Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes

Current Medical Research and Opinion

Volumn 22, Issue 5, 2006, Pages 861-872

  Palmer, Andrew J ^a   Dinneen, Sean ^b   Gavin III, James R ^c   Gray, Alastair ^d   Herman, William H ^e   Karter, Andrew J ^f  

^a IQVIA   (United States)

^b UNIVERSITY HOSPITAL GALWAY   (Ireland)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^f DIVISION OF RESEARCH   (United States)

Author keywords

Complications; Cost effectiveness; Costs; Self monitoring of blood glucose (SMBG); Type 2 diabetes; United Kingdom

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST UTILITY ANALYSIS; DIET THERAPY; EXERCISE; EYE DISEASE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INCIDENCE; KIDNEY DISEASE; MONTE CARLO METHOD; NATIONAL HEALTH SERVICE; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; REVIEW; SELF MONITORING; SENSITIVITY ANALYSIS; UNITED KINGDOM;

BLOOD GLUCOSE SELF-MONITORING; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS; STATE MEDICINE; TREATMENT OUTCOME;

EID: 33745023859     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X104669     Document Type: Review

References (50)

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53
2. International Diabetes Federation. Facts and figures: did you know? www.idf.org/home/index.cfm?node=6 (last accessed November, 2004)
3. The DCCT Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995;47:1703-20
4. Anon. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. J Am Med Assoc 2002;287:2563-9
5. UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998;317:703-13
6. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17
7. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. J Am Med Assoc 2004;291:335-42
8. Koro CE, Bowlin SJ, Bourgeois N, et al. Glycaemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20
9. Ubink-Veltmaat LJ, Bilo HJ, Groenier KH, et al. Prevalence, incidence and mortality of type 2 diabetes mellitus revisited: a prospective population-based study in The Netherlands (ZODIAC-1). Eur J Epidemiol 2003;18:793-800
10. Gatling W, Budd S, Walters D, et al. Evidence of an increasing prevalence of diagnosed diabetes mellitus in the Poole area from 1983 to 1996. Diabetic Med 1998;15:1015-21
11. Berger B, Stenstrom G, Sundkvist G. Incidence, prevalence, and mortality of diabetes in a large population. A report from the Skaraborg Diabetes Registry. Diabetes Care 1999;22:773-8
12. Sarol Jr JN, Nicodemus Jr NA, Tan KM, et al. Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966-2004). Curr Med Res Opin 2005;21:173-84
13. Welschen LM, Bloemendal E, Nijpels G, et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin. Cochrane Database Syst Rev 2005;2:CD005060
14. Welschen LM, Bloemendal E, Nijpels G, et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. Diabetes Care 2005;28: 1510-7
15. Bergenstal RM, Gavin III JR. The role of self-monitoring of blood glucose in the care of people with diabetes: report of a global consensus conference. Am J Med 2005;118(Suppl 9A):1S-6S
16. Standards of medical care in diabetes. Diabetes Care 2004;27(Suppl 1):S15-S35
17. American Association of Clinical Endocrinologists. Medical guidelines for the management of diabetes mellitus [report published in 2002]
18. Mayfield J, Havas S; for the AAFP Panel on Self-Monitoring of Blood Glucose. Self-control: a physician's guide to blood glucose control monitoring in the management of diabetes. An American Family Physician Monograph, www.aafp.org/x25813. xml (last accessed February 2005)
19. Canadian Diabetes Association. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003;27(Suppl 2): S1-S152
20. Burgers JS, Bailey JV, Klazinga NS, et al. Inside guidelines: comparative analysis of recommendations and evidence in diabetes guidelines from 13 countries. Diabetes Care 2002;25:1933-9
21. Anon. Follow-up of the type 2 diabetic patient excluding follow-up of complications. [Recommendations of ANAES]. Diabetes Metab 1999;25(Suppl 2):1-64
22. Karter AJ, Ackerson LM, Darbinian JA, et al. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. Am J Med 2001;111:1-9
23. Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (Types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl 1):S5-S26
24. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(Suppl 1):S27-S40
25. Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes. Diabetologia 2004;47:622-9
26. Primatesta P, Poulter NR. Lipid levels and the use of lipid-lowering agents in England and Scotland. Eur J Cardiovasc Prev Rehabil 2004;11:484-8
27. Wilson A, Baker R, Thompson J, et al. Coverage in screening for diabetic retinopathy according to screening provision: results from a national survey in England and Wales. Diabetic Med 2004;21:271-8
28. Benett IJ, Lambert C, Hinds G, et al. Emerging standards for diabetes care from a city-wide primary care audit. Diabetic Med 1994;11:489-92
29. Valentine WJ, Palmer AJ, Lammert M, et al. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting. Curr Med Res Opin 2005;21:2063-71
30. Coster S, Gulliford MC, Seed PT, et al., editors. Monitoring blood glucose control in diabetes mellitus: a systematic review. Health Technol Assess 2000;4(12)
31. Albisser AM, Sakkal S, Wright C. Home blood glucose prediction: validation, safety, and efficacy testing in clinical diabetes. Diabetes Technol Ther 2005;7:487-96
32. Kovatchev BP, Cox DJ, Kumar A, et al. Algorithmic evaluation of metabolic control and risk of severe hypoglycemia in type 1 and type 2 diabetes using self-monitoring blood glucose data. Diabetes Technol Ther 2003;5:817-28
33. Murata GH, Shah JH, Hoffman RM, et al. Intensified blood glucose monitoring improves glycemic control in stable, insulin-treated veterans with type 2 diabetes: the Diabetes Outcomes in Veterans Study (DOVES). Diabetes Care 2003;26:1759-63
34. Vincze G, Barner JC, Lopez D. Factors associated with adherence to self-monitoring of blood glucose among persons with diabetes. Diabetes Educ 2004;30:112-25
35. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in Type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-5
36. Clarke P, Gray A, Legood R, et al. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabetic Med 2003;20:442-50
37. Department of Health. NHS Reference Costs 2003 and National Tariff 2004. http://www.dh.gov.uk/PublicationsAndStatistics/Publications/ PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en? CONTENT_ ID=4070195&chk=UzhHA3 (last accessed April 2004)
38. Netten A, Curtis L. Unit costs of health and social care 2003. http://www.pssru.ac.uk/pdf/uc2003/uc2003_inflation.pdf (last accessed November 2005)
39. Grieve R, Beech R, Vincent J, et al. Near patient testing in diabetes clinics: appraising the costs and outcomes. Health Technol Assess 1999;3(15)
40. Gray A, Raikou M, McGuire A, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41) [United Kingdom Prospective Diabetes Study Group]. Br Med J 2000;320:1373-8
41. Schwedes U, Siebolds M, Mertes G. Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non-insulin-treated type 2 diabetic patients. Diabetes Care 2002;25:1928-32
42. Muchmore DB, Springer J, Miller M. Self-monitoring of blood glucose in overweight type 2 diabetic patients. Acta Diabetol 1994;31:215-9
43. Coffey JT, Brandle M, Zhou H, et al. Valuing health-related quality of life in diabetes. Diabetes Care 2002;25:2238-43
44. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-40
45. Smith TJ, Hillner BE, Schmitz N, et al. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol 1997;15:5-10
46. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004;13:437-52
47. Welschen LM, Bloemendal E, Nijpels G, et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: response to Kleefstra et al. and Davidson. Diabetes Care 2005;28:2597a-2598a
48. Guerci B, Drouin P, Grange V, et al. Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the Auto-Surveillance Intervention Active (ASIA) study. Diabetes Metab 2003;29:587-94
49. Franciosi M, Pellegrini F, De Berardis G, et al. The impact of blood glucose self-monitoring on metabolic control and quality of life in type 2 diabetic patients: an urgent need for better educational strategies. Diabetes Care 2001;24:1870-7
50. Schiel R, Muller UA, Rauchfub J, et al. Blood-glucose self-monitoring in insulin treated type 2 diabetes mellitus a cross-sectional study with an intervention group. Diabetes Metab 1999;25:334-40